| Autor: |
AlMutairi N; Department of Medicine, Faculty of Medicine, Kuwait University , Kuwait City, Kuwait., Eassa BI; Department of Dermatology, Farwaniya Hospital , Kuwait City, Kuwait. |
| Jazyk: |
angličtina |
| Zdroj: |
Expert opinion on biological therapy [Expert Opin Biol Ther] 2021 Feb; Vol. 21 (2), pp. 297-298. Date of Electronic Publication: 2020 Nov 09. |
| DOI: |
10.1080/14712598.2021.1843629 |
| Abstrakt: |
Introduction : There is limited data on the effects of biologic therapies on genital psoriasis and sexual activity. Recently, Ixekizumab was reported to be effective. Aim : To compare the efficacy of ixekizumab and secukinumab for the treatment of genital psoriasis and sexual inadequacy in adult patients with moderate-to-severe psoriasis. Patients and methods : We assessed adult patients with moderate-to-severe psoriasis having genital involvement. They were randomly assigned in a 1:1 ratio to receive either ixekizumab (80 mg/2 weeks after 160-mg initial dose) or secukinumab (300 mg subcutaneous injection at Weeks 0, 1, 2, 3, and 4 then every 4 weeks). The severity was assessed using Genital Psoriasis Symptoms Scale (GPSS), and impact on sexual health by evaluating the Massachusetts General Hospital-Sexual Functioning Questionnaire (MGH-SFQ). Results : Twenty eight patients on ixekizumab, and 26 on secukinumab showed improvement in genital psoriasis symptoms, beginning week 2 (GPSS total and individual items), and from week 4 onwards, improvement in sexual activity was seen with both drugs. Conclusion : Both genital psoriasis symptoms and impact on sexual activity improved rapidly and significantly with both the IL-17 inhibitors. Limitations included small number of patients and lack of follow-up period. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
